Max Healthcare Reports Strong Q2 Growth; Brokers Maintain Buy Ratings with Targets up to Rs 1,300
Max Healthcare Institute reported strong Q2 FY27 results with 18% year-on-year growth in revenue and EBITDA, supported by bed capacity expansions and improved operational efficiency. Occupancy remained steady at 77%, while ARPP increased by 8%. The company plans further brownfield and greenfield expansions, aiming to add over 800 beds in the coming quarters. Brokerage firms maintain 'Buy' ratings with target prices ranging from Rs 1,080 to Rs 1,300, citing growth prospects from capacity additions, margin recovery, and diversification into diagnostics and homecare services.
First-hand measurement across 5 sources
We measured how 5 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (70/100). Lens Score 32/100.
Outlets measured: moneycontrol, moneycontrol, moneycontrol, moneycontrol, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 4 Nov, 05:23 am. Other outlets followed.